Fragment screening by biochemical assay
暂无分享,去创建一个
Mark Whittaker | Thomas Hesterkamp | Steve Courtney | D. Ullmann | T. Hesterkamp | J. Barker | M. Whittaker | S. Courtney | Dirk Ullmann | John Barker
[1] Vicki L. Nienaber,et al. Discovering novel ligands for macromolecules using X-ray crystallographic screening , 2000, Nature Biotechnology.
[2] B R Baker,et al. Irreversible enzyme inhibitors. CVI. Proteolytic enzymes. I. Bulk tolerances in trypsin-inhibitor complexes. , 1967, Journal of medicinal chemistry.
[3] M. Congreve,et al. Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.
[4] J. Ellman,et al. Substrate activity screening: a fragment-based method for the rapid identification of nonpeptidic protease inhibitors. , 2005, Journal of the American Chemical Society.
[5] Jeremy R Everett,et al. NanoStore: A Concept for Logistical Improvements of Compound Handling in High-Throughput Screening , 2005, Journal of biomolecular screening.
[6] Dustin J Maly,et al. Combinatorial target-guided ligand assembly: identification of potent subtype-selective c-Src inhibitors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[7] Robert Schweitzer,et al. Comparison of Assay Technologies for a Tyrosine Kinase Assay Generates Different Results in High Throughput Screening , 2002, Journal of biomolecular screening.
[8] William W. Cohen,et al. Studies on the Active Center of Trypsin , 2003 .
[9] T. Gadek,et al. Discovery of novel PTP1b inhibitors. , 2004, Bioorganic & medicinal chemistry letters.
[10] Bohdan Waszkowycz,et al. PRO_SELECT: combining structure-based drug design and array-based chemistry for rapid lead discovery. 2. The development of a series of highly potent and selective factor Xa inhibitors. , 2002, Journal of medicinal chemistry.
[11] Edward R Zartler,et al. Fragonomics: fragment-based drug discovery. , 2005, Current opinion in chemical biology.
[12] Andreas Sewing,et al. Fluorescence readouts in HTS: no gain without pain? , 2003, Drug discovery today.
[13] Jeffrey W. Peng,et al. Theory and applications of NMR-based screening in pharmaceutical research. , 2004, Chemical reviews.
[14] Kazuo Shinozaki,et al. A structure‐based strategy for discovery of small ligands binding to functionally unknown proteins: Combination of in silico screening and surface plasmon resonance measurements , 2005, Proteomics.
[15] C. Eggeling,et al. New fluorescence techniques for high-throughput drug discovery. , 2003, Current pharmaceutical biotechnology.
[16] M. Congreve,et al. A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.
[17] Gianni Chessari,et al. Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors. , 2006, Journal of medicinal chemistry.
[18] C. Craik,et al. Design and synthesis of novel inhibitors of gelatinase B. , 2002, Bioorganic & medicinal chemistry letters.
[19] B. Shoichet,et al. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.
[20] C. Chung,et al. Effect of detergent on "promiscuous" inhibitors. , 2003, Journal of medicinal chemistry.
[21] J. T. Metz,et al. Ligand efficiency indices as guideposts for drug discovery. , 2005, Drug discovery today.
[22] Christian Eggeling,et al. Highly sensitive fluorescence detection technology currently available for HTS. , 2003, Drug discovery today.
[23] Nicola Mongelli,et al. A general NMR method for rapid, efficient, and reliable biochemical screening. , 2003, Journal of the American Chemical Society.
[24] Tudor I. Oprea,et al. Pursuing the leadlikeness concept in pharmaceutical research. , 2004, Current opinion in chemical biology.
[25] Jean M. Severin,et al. Discovery of potent inhibitors of dihydroneopterin aldolase using CrystaLEAD high-throughput X-ray crystallographic screening and structure-directed lead optimization. , 2004, Journal of medicinal chemistry.
[26] P. Hajduk,et al. High-throughput nuclear magnetic resonance-based screening. , 1999, Journal of medicinal chemistry.
[27] P. Hajduk,et al. SOS-NMR: a saturation transfer NMR-based method for determining the structures of protein-ligand complexes. , 2004, Journal of the American Chemical Society.
[28] D. Wyss,et al. Competition STD NMR for the detection of high‐affinity ligands and NMR‐based screening , 2004, Magnetic resonance in chemistry : MRC.
[29] Daniel A Erlanson,et al. Making drugs on proteins: site-directed ligand discovery for fragment-based lead assembly. , 2004, Current opinion in chemical biology.
[30] U. Haupts,et al. Macroscopic versus microscopic fluorescence techniques in (ultra)-high-throughput screening , 2000 .
[31] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[32] Matthew A. Cooper,et al. Optical biosensors in drug discovery , 2002, Nature Reviews Drug Discovery.
[33] Tudor I. Oprea,et al. Is There a Difference between Leads and Drugs? A Historical Perspective , 2001, J. Chem. Inf. Comput. Sci..
[34] E. Shaw,et al. Studies on the active center of trypsin. Further characterization of the hydrophobic binding site. , 1967, The Journal of biological chemistry.
[35] R. Liskamp,et al. Surface plasmon resonance thermodynamic and kinetic analysis as a strategic tool in drug design. Distinct ways for phosphopeptides to plug into Src- and Grb2 SH2 domains. , 2005, Journal of medicinal chemistry.
[36] D. Fattori,et al. Molecular recognition: the fragment approach in lead generation. , 2004, Drug discovery today.
[37] A. Sharff,et al. High-throughput crystallography to enhance drug discovery. , 2003, Current opinion in chemical biology.
[38] H. Matter,et al. Custom chemical microarray production and affinity fingerprinting for the S1 pocket of factor VIIa. , 2004, Analytical biochemistry.
[39] D. Kostrewa,et al. Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. , 2000, Journal of medicinal chemistry.
[40] Elena Conti,et al. X‐ray and spectrophotometric studies of the binding of proflavin to the S1 specificity pocket of human α‐thrombin , 1998 .
[41] P. Hajduk,et al. Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.
[42] Markus Schade,et al. NMR fragment screening: Advantages and applications. , 2006, IDrugs : the investigational drugs journal.
[43] Andrew R. Leach,et al. Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..
[44] A. Hopkins,et al. Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.
[45] Nicola Mongelli,et al. Sensitivity improvement in 19F NMR-based screening experiments: theoretical considerations and experimental applications. , 2005, Journal of the American Chemical Society.
[46] K. Breuker. New mass spectrometric methods for the quantification of protein-ligand binding in solution. , 2004, Angewandte Chemie.
[47] Dustin J Maly,et al. Tyrosylprotein sulfotransferase inhibitors generated by combinatorial target-guided ligand assembly. , 2002, Bioorganic & medicinal chemistry letters.
[48] Hugo O Villar,et al. Using NMR for ligand discovery and optimization. , 2004, Current opinion in chemical biology.
[49] Christopher W Murray,et al. Fragment-based lead discovery using X-ray crystallography. , 2005, Journal of medicinal chemistry.
[50] D. Vetter. Chemical microarrays, fragment diversity, label‐free imaging by plasmon resonance—a chemical genomics approach , 2002, Journal of cellular biochemistry. Supplement.
[51] B. Shoichet,et al. A specific mechanism of nonspecific inhibition. , 2003, Journal of medicinal chemistry.
[52] Brian Dymock,et al. Design and Characterization of Libraries of Molecular Fragments for Use in NMR Screening against Protein Targets , 2004, J. Chem. Inf. Model..
[53] Jeffrey W. Peng,et al. Applications of SHAPES screening in drug discovery. , 2002, Combinatorial chemistry & high throughput screening.
[54] B. Shoichet,et al. Identification and prediction of promiscuous aggregating inhibitors among known drugs. , 2003, Journal of medicinal chemistry.
[55] Christopher W Murray,et al. Fragment-based lead discovery: leads by design. , 2005, Drug discovery today.
[56] Edgar Jacoby,et al. Library design for fragment based screening. , 2005, Current topics in medicinal chemistry.
[57] Manfred Auer,et al. Fluorescence correlation spectroscopy: Lead discovery by miniaturized HTS , 1998 .
[58] J Fraser Glickman,et al. Comparison of Assay Technologies for a Nuclear Receptor Assay Screen Reveals Differences in the Sets of Identified Functional Antagonists , 2003, Journal of biomolecular screening.
[59] Wolfgang Jahnke,et al. Second-site NMR screening and linker design. , 2003, Current topics in medicinal chemistry.
[60] Christian Eggeling,et al. Experiences in implementing uHTS--cutting edge technology meets the real world. , 2004, Current drug discovery technologies.
[61] T. Gadek,et al. Structure-activity relationships by mass spectrometry: identification of novel MMP-3 inhibitors. , 2004, Bioorganic & medicinal chemistry.
[62] Kam Y. J. Zhang,et al. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design , 2005, Nature Biotechnology.
[63] Gang Liu,et al. Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy. , 2003, Journal of the American Chemical Society.